Raja Mehanna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7996819/publications.pdf

Version: 2024-02-01

840776 713466 23 730 11 21 citations h-index g-index papers 23 23 23 1065 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Movement disorders in cerebrovascular disease. Lancet Neurology, The, 2013, 12, 597-608.	10.2	195
2	Respiratory problems in neurologic movement disorders. Parkinsonism and Related Disorders, 2010, 16, 628-638.	2.2	127
3	Movement disorders in multiple sclerosis and other demyelinating diseases. Journal of the Neurological Sciences, 2013, 328, 1-8.	0.6	82
4	Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism and Related Disorders, 2019, 65, 39-48.	2.2	69
5	DBS Programming: An Evolving Approach for Patients with Parkinson's Disease. Parkinson's Disease, 2017, 2017, 1-11.	1.1	46
6	Analysis of <i><scp>CYP2D6</scp></i> genotype and response to tetrabenazine. Movement Disorders, 2013, 28, 210-215.	3.9	42
7	Deep brain stimulation in Parkinson's disease. Translational Neurodegeneration, 2013, 2, 22.	8.0	41
8	Comprehensive, Multidisciplinary <scp>Deep Brain Stimulation < /scp> Screening for Parkinson Patients: No Room for "Short Cuts― Movement Disorders Clinical Practice, 2014, 1, 336-341.</scp>	1.5	25
9	Cognitive Impact of Deep Brain Stimulation on Parkinson's Disease Patients. Parkinson's Disease, 2017, 2017, 1-15.	1.1	25
10	Amyotrophic Lateral Sclerosis With Positive Anti-Acetylcholine Receptor Antibodies. Case Report and Review of the Literature. Journal of Clinical Neuromuscular Disease, 2012, 14, 82-85.	0.7	24
11	Respiratory disorders associated with dystonia. Movement Disorders, 2012, 27, 1816-1819.	3.9	20
12	Rationale and patient selection for interventional therapies in Parkinson's disease. Expert Review of Neurotherapeutics, 2018, 18, 811-823.	2.8	8
13	Deep Brain Stimulation in Parkinson's Disease. Parkinson's Disease, 2018, 2018, 1-2.	1.1	5
14	Comparing subjective and objective response to medications in Parkinson's disease patients using the Personal KinetiGraphâ,,¢. Parkinsonism and Related Disorders, 2021, 87, 105-110.	2.2	5
15	Drug induced parkinsonism: Symptomatic beyond 22 months. Parkinsonism and Related Disorders, 2019, 66, 267-268.	2.2	3
16	Gastrointestinal disorders in hyperkinetic movement disorders and ataxia. Parkinsonism and Related Disorders, 2021, 90, 125-133.	2.2	3
17	Olfactory hallucinations as a non-motor sign of Parkinson's disease – A cross sectional study amongst patients in a tertiary movement disorder center. Parkinsonism and Related Disorders, 2022, 99, 30-32.	2.2	3
18	End of life. Neurology, 2019, 93, 10.1212/WNL.00000000008356.	1.1	2

#	Article	IF	CITATIONS
19	Movement Disorders in Multiple Sclerosis and Other Demyelinating Diseases. Neurologist, 2021, 26, 161-166.	0.7	2
20	Cognitive Changes after Deep Brain Stimulation in Parkinson's Disease: A Critical Review. Brain Disorders & Therapy, 2014, 03, .	0.1	2
21	"l am not depressed. I just don't like myself― stigma and (lack of) depression in a subset of patients with Parkinson's disease. Revista Brasileira De Psiquiatria, 2020, 42, 124-125.	1.7	1
22	Respiratory complications of movement disorders., 0,, 398-418.		0
23	Are functional movement disorder phenotypes or age at onset correlated with perfectionism or history of abuse?. Clinical Parkinsonism & Related Disorders, 2021, 4, 100099.	0.9	0